Navigation Links
Aton Pharma Launches Authorized Generic Version of Glaucoma Eye Drop Timoptic-XE(R) Gel Forming Solution

LAWRENCEVILLE, N.J., March 9 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

"Authorized generics are a very effective sales strategy for Aton Pharma's product portfolio," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "We are extremely pleased with the successful launch of the authorized generic for Timoptic-XE and we are now highly confident in our ability to execute this type of program for other Aton products when the opportunity arises."

Aton's U.S. Timoptic product line includes Timoptic (timolol maleate) Ophthalmic Solution, Timoptic (timolol maleate ophthalmic solution) in Ocudose® (sterile ophthalmic unit dose dispenser) and Timoptic-XE (timolol maleate ophthalmic gel forming solution) Ophthalmic and now an authorized generic form of this branded product.

Timoptic in Ocudose is the only preservative-free medication for glaucoma available in the U.S. and aligns with Aton's strategy of providing unique, medically essential products.

Timoptic is indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Timoptic is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. The most frequent adverse events have been burning and stinging upon installation.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see

SOURCE Aton Pharma, Inc.

Back to top



SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
(Date:12/1/2015)... , Dec. 1, 2015  ImmunoCellular Therapeutics, ... Andrew Gengos , President and Chief ... on December 3, 2015. Mr. Gengos plans ... registrational program in patients with newly diagnosed ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
(Date:12/1/2015)... and UPPSALA, Sweden , December ... been selected by the International Breast Cancer Study Group (IBCSG, ... (BIG, Brussels ) to be part of ... palbociclib, a promising new cancer drug.  --> ... women with advanced breast cancer being treated with anti-hormonal therapy ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):